| Literature DB >> 23071929 |
Mayur A Chordiya1, Hemant H Gangurde, K Senthilkumaran, Lokesh P Kothari.
Abstract
BACKGROUND: The main aim of this study was to develop a gastroretentive, multiple-unit floating drug delivery system for a drug which is poorly absorbed from the lower gastrointestinal tract. Such a dosage form may provide an extended retention of drug in the upper gastrointestinal tract resulting in enhanced absorption and improved bioavailability.Entities:
Keywords: Cellulose acetate; Eudragit RL 100; Higuchi's model; emulsion solvent diffusion; scanning electron microscopy
Year: 2011 PMID: 23071929 PMCID: PMC3465131 DOI: 10.4103/2230-973X.82423
Source DB: PubMed Journal: Int J Pharm Investig ISSN: 2230-9713
Formulation of floating hollow microspheres, E1–E4, of famotidine
Formulations of famotidine's floating hollow microspheres, C1–C4
Figure 1aIR spectrum of famotidine (500-2000 cm-1)
Figure 1bIR spectrum of famotidine (2000-4000 cm-1)
Interpretation of the IR spectrum of famotidine
Figure 2IR spectrum of Eudragit RL 100
Figure 5IR spectrum of famotidine + cellulose acetate (1:1)
Particle size of formulations E1–E4 and C1–C4
Drug entrapment efficiency of formulations (E1–E4 and C1–C4)
Buoyancy percentage of formulations E1–E4 and C1–C4
In vitro drug release profile for formulations E1–E4
Figure 6Comparison of the in vitro drug release profiles for formulations E1–E4
In vitro drug release profile for formulations C1–C4
Figure 7Comparison of in vitro drug release profiles for formulations C1–C4
In vitro kinetics data for formulations E1–E4 and C1–C4
Figure 8Scanning electron microphotographs of floating hollow microspheres of famotidine: (a) and (b) surface and cross-sectional morphology of C1-A, respectively; (c) and (d) surface and cross-sectional morphology of the formulation E1-A, respectively